Maxim Group Keeps Their Buy Rating on Omeros (OMER)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Omeros (OMERResearch Report), with a price target of $25.00. The company’s shares closed last Monday at $14.04.

According to, McCarthy is ranked 0 out of 5 stars with an average return of -22.0% and a 25.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros with a $26.50 average price target, implying an 83.9% upside from current levels. In a report issued on October 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.92 and a one-year low of $10.30. Currently, Omeros has an average volume of 420.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.